Valuentum Exclusive Analysis for the Discerning Investor

Symbol Keyword

Feb 1, 2021

Two Industrial Giants on the Rebound
Image Source: Honeywell International Inc – Fourth Quarter of 2020 IR Earnings Presentation. Two industrial bellwethers reported fourth-quarter earnings for 2020 recently, Caterpillar and Honeywell. Industrial companies were hit extremely hard by the coronavirus (‘COVID-19’) pandemic last year due to a myriad of factors from production lines getting shut down to deteriorating end-user demand, though things are starting to improve as global health authorities steadily work towards putting an end to the public health crisis now that vaccine distribution activities are underway. Both industrial firms covered in this note mentioned that they expect their financial and operational performance to improve going forward.

Jan 29, 2021

More Earnings Reports: BA, CMCSA, MCD
Image Shown: Though the past year has been brutal for the commercial airliner and aerospace industries, and it will continue to be rough sledding in the near term, Boeing is optimistic that within a few years passenger traffic will return to pre-pandemic levels and resume its growth trajectory thereafter. Image Source: Boeing Company – Fourth Quarter of 2020 IR Earnings Presentation. We are continuing with our coverage of key earnings reports. Ongoing vaccine distribution activities should help global health authorities bring the coronavirus (‘COVID-19’) pandemic under control, though risks remain as new variants of the virus are popping up all over the place (and then spreading aggressively). In this article, we cover the recent earnings reports from Boeing, Comcast, and McDonald's.

Jan 29, 2021

Starbucks Expects to Recover in Fiscal 2021
Image Shown: Shares of Starbucks Corporation appear fairly valued at this time. The top end of our fair value estimate range sits at $100 per share of SBUX.We're reiterating our fair value estimate of $80 per share of Starbucks, and the top end of our fair value estimate range sits at $100 per share. As of this writing, shares of Starbucks appear to be fairly valued at this time. While Starbucks’ operations are rebounding and its guidance for fiscal 2021 indicates the firm expects ongoing COVID-19 vaccine distribution activities will have a powerful impact on its near-term financial performance, the firm’s current share price already takes into consideration its pending recovery, in our view. We are not interested in adding Starbucks to any of our newsletter portfolios at this time.

Jan 29, 2021

Dividend Increases/Decreases for the Week January 29
Let's take a look at companies that raised/lowered their dividend this week.

Jan 28, 2021

Fourth Quarter Bank Earnings Roundup: MS, GS, BAC, C, WFC, JPM
Image Source: JP Morgan’s fourth-quarter earnings press release. Though we’re generally cautious on banking business models due to the arbitrary nature of cash-flow generation within the banking system and the difficulty in valuing such entities on the basis of a free-cash-flow-to-the firm framework, we like Morgan Stanley--and its return on tangible equity of 17.7% during the fourth quarter of 2020 speaks to solid economic-value creation. Goldman’s annualized return on total equity (ROTE) was an impressive 22.5% during its fourth quarter, helping drive the full-year measure to 11.1% for 2020. Bank of America had been an idea in the Best Ideas Newsletter portfolio in the past, but we removed the company June 11, 2020. We continue to view the banking system more as utility-like serving as an extension of the federal government, and as such, we generally don’t think they’ll be able to muster above-average returns in the longer-run. We still include diversified exposure to the financial sector in the Best Ideas Newsletter portfolio via the Financial Select Sector SPDR (XLF), but only for diversification purposes. Citigroup remains among our least favorite banking entities. Wells Fargo used to be a well-run bank, but consumer perception has certainly changed with its “fake account scandal” that cost it $3 billion to settle criminal and civil charges. JP Morgan's return metrics were solid like Morgan Stanley’s and Goldman’s, with return on equity (ROE) coming in at 19% and return on total common equity (ROTCE) coming in at 24% in the quarter. The banking system remains on stable ground.

Jan 28, 2021

Three Newsletter Portfolio Ideas Post Stellar Earnings Updates: JNJ, LMT, MSFT
Image Source: Johnson & Johnson – Fourth Quarter of Fiscal 2020 Earnings IR Presentation. Earnings season is now underway and so far, we are quite impressed with the performance of the ideas included in the newsletter portfolios. Johnson & Johnson and Lockheed Martin are both on the rebound while Microsoft continues to be an “unstoppable” growth juggernaut. All three of these firms have stellar free cash flow generating abilities and have promising growth outlooks, which underpins why we are big fans of each company.

Jan 28, 2021

Earnings Roundup of Three High-Yielding Firms: MMM, RTX, VZ
Image Source: 3M Company – Fourth Quarter of 2020 Earnings IR Presentation. The coronavirus (‘COVID-19’) pandemic generated substantial headwinds for the global economy in 2020 and for most businesses large and small, save for many firms operating in the IT sector. However, several large industrial and telecommunications companies are reporting that the outlook for 2021 looks quite bright, relatively speaking, as ongoing vaccine distribution efforts indicate the pandemic will be brought to an end sooner than expected. In this article, let's examine the recent earnings reports from 3M, Raytheon Technologies, and Verizon Communications. Our fair value estimate on S&P 500 stands at 3,530-3,920.

Jan 27, 2021

Fourth Quarter Earnings Reports Coming In: INTC, GGG, KMB, STLD
Image Source: Kimberly Clark Corporation – Second Quarter of Fiscal 2021 Earnings IR Presentation. Fourth quarter 2020 earnings season is upon us. In this note, we walk through the reports of four companies issuing results: Intel, Graco, Kimberly Clark, and Steel Dynamics. Intel is making the right call by seeking to outsource some of its production needs given its inability to produce certain current- and next-generation chips. For companies operating in the industrial sector, it appears that after a challenging first half of 2020, things are now recovering in earnest. The industrial economy appears to have entered 2021 with momentum, keeping short-term headwinds in mind. Consumer staples entities experienced strong demand growth in 2020, though it appears that many companies operating in the space now expect their organic sales growth to moderate in 2021 as the uplift from “pantry stockpiling” fades.

Jan 24, 2021

Following Up on Leading Semiconductor Equipment Supplier ASML Holding N.V.
Image Source: ASML Holding NV – Fourth Quarter and Full-Year 2020 Earnings IR Presentation. Shares of Netherlands-based ASML Holding N.V., which supplies lithography systems and services to the semiconductor industry, have done incredibly well since we published our note, "ASML Holding Is an Impressive Enterprise with a Pristine Balance Sheet and Rock-Solid Growth Trajectory" article back on April 8, 2020. From April 8 to January 22, shares of ASML more than doubled. We strongly encourage members that have not done so to check out that article, as we laid out how ASML Holding’s lithography systems are an essential part of the semiconductor industry along with our reasoning behind why we view the company’s long-term outlook favorably. We continue to be fans of ASML Holding’s business model. As a leader in an industry supported by numerous secular growth tailwinds (secular trends, such as the rise of AI and cloud-computing, support the outlook for semiconductor demand which in turn supports the outlook for the cutting edge lithography systems used to make these semiconductors), ASML Holding is poised to continue to generate strong revenue growth while maintaining its pricing power.

Jan 24, 2021

Best Idea Vertex Pharma Is an Intriguing Biotech Play
Image Shown: A snapshot of Vertex Pharmaceuticals Inc’s approved therapeutic offerings and its drug pipeline. Image Source: Vertex Pharmaceuticals Inc – January 2021 IR Presentation. Vertex’s market leading position in the cystic fibrosis ('CF') therapeutics space underpins our expectations that its free cash flow will grow at a brisk pace going forward (supported by the potential for the company to expand into new markets and the potential to grow the application of its CF portfolio). We also like Vertex’s exposure to gene therapies via its partnership with CRISPR Therapeutics. Vertex’s existing drug pipeline is decent, and the biotech has the ability to use its net cash position to bulk up its drug pipeline even further if needed (through a strategic partnership, acquisition, purchase of drug development rights, etc.). Though we generally don't get too excited about biotech plays given their speculative nature, the difficulty in predicting the success of drugs in their pipeline, and the potential for shareholder dilution via new equity issuance, Vertex’s financial position is rock-solid, its outlook is bright, and we like having exposure to the company in the Best Ideas Newsletter portfolio.